Biofrontera AG
B8FK
Company Profile
Business description
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.
Contact
Hemmelrather Weg 201
LeverkusenNW51377
DEUT: +49 2148763200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2024
Employees
80
Stocks News & Analysis
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
stocks
The market hates this compelling ASX income play
Santos continues to trade at a valuation that implies no growth in the years ahead. Our analyst Mark Taylor thinks that is misguided.
stocks
Lessons from the top performing ASX share
Chasing performance can lead to poor results but investors can still learn from top performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,719.60 | 35.10 | -0.40% |
| CAC 40 | 7,255.42 | 18.53 | 0.26% |
| DAX 40 | 20,016.75 | 83.13 | 0.42% |
| Dow JONES (US) | 44,705.53 | 76.47 | -0.17% |
| FTSE 100 | 8,359.41 | 46.52 | 0.56% |
| HKSE | 19,746.32 | 196.03 | 1.00% |
| NASDAQ | 19,480.91 | 76.96 | 0.40% |
| Nikkei 225 | 39,354.00 | 105.14 | 0.27% |
| NZX 50 Index | 12,937.13 | 156.05 | -1.19% |
| S&P 500 | 6,049.88 | 2.73 | 0.05% |
| S&P/ASX 200 | 8,455.50 | 39.70 | -0.47% |
| SSE Composite Index | 3,378.81 | 14.82 | 0.44% |